Clinical Adoption of Prognostic Biomarkers The Case for Heart Failure

• Type of Material: Article
• Authors: Andreas Kalogeropoulos, Emory University; Vasiliki (Vicki) Georgiopoulou, Emory University; Javed Butler, Emory University
• Language: English
• Date: 2012
• Publisher: WB Saunders
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2012 Elsevier Inc. All rights reserved.
• License: Creative Commons Attribution-NonCommerical-NoDerivs 3.0 Unported
• Final Published Version (URL): http://dx.doi.org/10.1016/j.pcad.2012.05.004
• Title of Journal or Parent Work: Progress in Cardiovascular Diseases
• ISSN: 0033-0620
• Volume: 55
• Issue: 1
• Start Page: 3
• End Page: 13
• Grant/Funding Information: Supported in part by (a) PHS Grant UL1 RR025008 from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources and (b) Grant 1U10HL110302-01 from the National Institutes of Health, National Heart, Lung, and Blood Institute.
• Research Categories: Health Sciences, Medicine and Surgery

Abstract

The recent explosion of scientific knowledge and technological progress has led to the discovery of a large array of circulating molecules commonly referred to as biomarkers. Biomarkers in heart failure research have been used to provide pathophysiological insights, aid in establishing the diagnosis, refine prognosis, guide management, and target treatment. However, beyond diagnostic applications of natriuretic peptides, there are currently few widely recognized applications for biomarkers in heart failure. This represents a remarkable discordance considering the number of molecules that have been shown to correlate with outcomes, refine risk prediction, or track disease severity in heart failure in the past decade. In this article, we use a broad framework proposed for cardiovascular risk markers to summarize the current state of biomarker development for heart failure patients. We utilize this framework to identify the challenges of biomarker adoption for risk prediction, disease management, and treatment selection for heart failure and suggest considerations for future research.